DP
TENX icon

Diadema Partners’s Tenax Therapeutics TENX Stock Holding History

Diadema Partners’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.87M Sell
179,738
-63,432
-26% -$858K 0.49% 50
2025
Q4 		$2.96M Buy
+243,170
New +$2.12M 0.51% 45

Other funds holding TENX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Diadema Partners's TENX Position: Q1 2026 in Review

Diadema Partners reduced its Tenax Therapeutics (TENX) stake by 26% in Q1 2026, selling an estimated $858K and leaving 179,738 shares worth $2.87M. The position accounts for 0.49% of the portfolio, ranked #50.

Diadema Partners first reported a position in TENX in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.96M in Q4 2025. 80 funds tracked by Wall St. Rank hold TENX as of Q1 2026.

  • Diadema Partners held 179,738 shares of Tenax Therapeutics worth $2.87M as of Q1 2026.
  • Diadema Partners sold 63,432 Tenax Therapeutics shares in Q1 2026, an estimated $858K.
  • Tenax Therapeutics made up 0.49% of Diadema Partners's portfolio in Q1 2026, its #50 holding.
  • Diadema Partners first reported a position in Tenax Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Diadema Partners's Tenax Therapeutics position peaked at $2.96M in Q4 2025.
  • 80 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.